400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
ChiCTR2500104716
尚未开始
/
/
/
2025-06-23
/
/
Glaucoma
A novel deep learning-based three-dimensional retinal vascular analysis for progression risk stratification in glaucoma patients
A novel deep learning-based three-dimensional retinal vascular analysis for progression risk stratification in glaucoma patients
Aim 1 • To develop a novel deep learning-based 3D model for retinal vasculature analysis in glaucoma patients. Aim 2 • To integrate the novel biomarkers of our proposed 3D DL retinal vasculature system with clinical biomarkers for the establishment of a risk stratification model of glaucoma progression.
诊断试验诊断准确性
其它
NA
/
Health and Medical Research Fund
/
/
/
2025-07-01
2027-04-30
/
1. Older than 18 years 2. Best corrected visual acuity (BCVA) no less than 20/40. 3. No severe systemic disorders (i.e., those without clinical retinal involvement). 4. Glaucoma is defined when at least one eye had the presence of the structural and functional evidence of glaucoma, including glaucomatous optic disc cupping, RNFL damage, or neuroretinal rim loss, and minimal criteria for glaucomatous VF defect as per published standard (38): glaucoma hemifield test result outside normal limits, pattern standard deviation (PSD) with P < 0.05 or a cluster of 3 or more points in the pattern deviation plot in a single hemifield with P < 0.05, one of which must have P < 0.01. Any one of the preceding criteria, if repeatable, was considered sufficient evidence for the glaucomatous visual field (VF) defect.;
请登录查看1. Other ocular diseases that may cause retinal vascular change, such as diabetic retinopathy, hypertension retinopathy; or AMD. 2. Extremely myopia (i.e., axial length > 27.0 mm). 3. OCTA images with insufficient image quality.;
请登录查看The Chinese University of Hong Kong
/
浙江道尔生物科技有限公司2026-04-16
新药创始人2026-04-16
丁香园 Insight 数据库2026-04-16
2021至2023年理赔服务2026-04-16
干细胞与外泌体2026-04-16
细胞与基因治疗领域2026-04-16
北京药研汇2026-04-16
正大天晴药业集团2026-04-16
复融生物2026-04-16
先通医药2026-04-16